

# Martin Busch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6171017/publications.pdf>

Version: 2024-02-01

25  
papers

918  
citations

567281  
15  
h-index

501196  
28  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1707  
citing authors

#	ARTICLE	IF	CITATIONS
1	Advanced glycation end-products and the kidney. European Journal of Clinical Investigation, 2010, 40, 742-755.	3.4	184
2	Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrology Dialysis Transplantation, 2015, 30, 441-451.	0.7	132
3	The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrology Dialysis Transplantation, 2012, 27, 1454-1460.	0.7	127
4	Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney International, 2004, 66, 338-347.	5.2	108
5	The Advanced Glycation End Product N <sup>ε</sup> -Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension. American Journal of Kidney Diseases, 2006, 48, 571-579.	1.9	59
6	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
7	Are advanced glycation end products cardiovascular risk factors in patients with CRF?. American Journal of Kidney Diseases, 2003, 41, S52-S56.	1.9	29
8	Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort. Journal of Internal Medicine, 2021, 290, 1219-1232.	6.0	27
9	Vitamin B <sub>6</sub> ; Metabolism in Chronic Kidney Disease – Relation to Transsulfuration, Advanced Glycation and Cardiovascular Disease. Nephron Clinical Practice, 2010, 114, c38-c46.	2.3	24
10	Mucosal-Associated Invariant T Cells Redistribute to the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to Peritoneal Inflammation. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 661-677.	4.5	24
11	Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney International, 2015, 88, 1411-1418.	5.2	23
12	Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study. PLoS ONE, 2018, 13, e0202604.	2.5	20
13	Serum Levels of the Advanced Glycation End Products N <sup>ε</sup> -Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension. Nephron Clinical Practice, 2008, 108, c291-c297.	2.3	18
14	Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrology, 2016, 17, 59.	1.8	18
15	Heart Failure in a Cohort of Patients with Chronic Kidney Disease: The GCKD Study. PLoS ONE, 2015, 10, e0122552.	2.5	18
16	Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. Journal of Clinical Medicine, 2020, 9, 886.	2.4	15
17	Rituximab for the second- and thirdline therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Clinical Nephrology, 2013, 80, 105-113.	0.7	13
18	Advanced Glycation End Products and Î² <sub>2</sub> -Microglobulin as Predictors of Carpal Tunnel Syndrome in Hemodialysis Patients. Blood Purification, 2012, 34, 3-9.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Rate, Factors, and Outcome of Delayed Graft Function After Kidney Transplantation of Deceased Donors. Transplantation Proceedings, 2021, 53, 1454-1461.	0.6	8
20	Validated capillary gas chromatographicâ€“mass spectrometric assay to determine 2-methylcitric acid I and II levels in human serum by using a pulsed splitless injection procedure. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 775, 215-223.	2.3	6
21	Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease of Different Stages â€“ A Follow-up Analysis of Health Insurance Data from Germany. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 821-830.	1.2	4
22	Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases. Diagnostics, 2022, 12, 67.	2.6	2
23	Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. CKJ: Clinical Kidney Journal, 2021, 14, 277-283.	2.9	1
24	FP155PREDICTORS OF RENAL INVOLVEMENT IN ANCA ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2018, 33, i81-i82.	0.7	0
25	Heart-Type Fatty Acid Binding Protein, Cardiovascular Outcomes, and Death: Findings From the German CKD Cohort Study. American Journal of Kidney Diseases, 2022, , .	1.9	0